Burning Rock Biotech (BNR) has released an update.
Burning Rock Biotech Limited reported a decrease in first-quarter revenue by 11.9% year-over-year due to a strategic shift towards in-hospital testing, despite the segment’s own revenue growing by 11.3%. The company saw a significant decrease in operating expenses, contributing to a reduced net loss compared to the previous year. Burning Rock also indicated a breakeven target for 2024, adjusting to a new corporate structure with its headquarters now in Guangzhou.
For further insights into BNR stock, check out TipRanks’ Stock Analysis page.
